Methodological and statistical aspects of equivalence and non inferiority trials;Aspects méthodologiques et statistiques des essais d'équivalence et de non-infériorité

Revue d'Epidemiologie et de Sante Publique

Volumn 56, Issue 4, 2008, Pages 267-277

  Elie, C ^a   De Rycke, Y ^b   Jais, J P ^a   Marion Gallois, R ^c   Landais, P ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSTITUT CURIE   (France)

^c Statelis   (France)

Author keywords

Confidence intervals; Equivalence trial; Noninferiority trial; Protocol; Randomized controlled trial

Indexed keywords

ARTICLE; CLINICAL STUDY; CONFIDENCE INTERVAL; HYPOTHESIS; METHODOLOGY; POPULATION RESEARCH; SAMPLE SIZE; STATISTICAL ANALYSIS;

EID: 55349137346     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respe.2008.05.027     Document Type: Short Survey

References (18)

1. Committee for Proprietary Medical Products (CPMP). Note for guidance on the Investigation of Bioavailability and bioequivalence. 2001. European Medicines Agency (EMEA). CPMP/EWP/QWP/1401/98.
2. Committee for Medicinal Products for Human use (CHMP). Questions and Answers on the Bioavailability and Bioequivalence Guideline. 2006. European Medicines Agency (EMEA). EMEA/CHMP/EWP/40326/2006.
3. Committee for Medicinal Products for Human use (CHMP). Recommendation on the need for revision of "note for guidance on the investigation of bioavailability and bioequivalence" CPMP/EWP/QWP/1401/98. 2007. European Medicines Agency (EMEA). EMEA/CHMP/EWP/200943/2007.
4. International Conference on Harmonisation. Statistical principles for clinical trials (ICH E9). 1998. Food and Drug Administration, Department of Health and Human Services.
5. International Conference on Harmonisation. Guidance on choice of control group and related design and conduct issues in clinical trials (ICH E10). 2000. Food and Drug Administration, Department of Health and Human Services.
6. D.G. Altman, K.F. Schulz, D. Moher, M. Egger, F. Davidoff, and D. Elbourne The revised CONSORT statement for reporting randomized trials: explanation and elaboration Ann Intern Med 134 2001 663 694
7. R.B. D'Agostino Sr., J.M. Massaro, and L.M. Sullivan Non inferiority trials: design concepts and issues - the encounters of academic consultants in statistics Stat Med 22 2003 169 186
8. D.J. Schuirmann A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability J Pharmacokinet Biopharm 15 1987 657 680
9. C.W. Dunnett, and M. Gent Significance testing to establish equivalence between treatments, with special reference to data in the form of 2 × 2 tables Biometrics 33 1977 593 602
10. C. Com-Nougue, C. Rodary, and C. Patte How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma Stat Med 12 1993 1353 1364
11. Committee for Proprietary Medical Products (CPMP). Point to Consider on switching between superiority and non-inferiority. 2000. European Medicines Agency (EMEA). CPMP/EWP/492/99.
12. P. Deheuvels How to analyse bioequivalence studies? The right use of confidence intervals J Organ Behav Stat 1 1984 1 15
13. Committee for Medicinal Products for Human use (CHMP). Guideline on the choice of the non-inferiority margin. 2006. European Medicines Agency (EMEA). EMEA/CPMP/EWP/2158/99.
14. S. Kaul, G.A. Diamond, and W.S. Weintraub Trials and tribulations of non-inferiority: the ximelagatran experience J Am Coll Cardiol 46 2005 1986 1995
15. P. Tubert-Bitter, R. Manfredi, J. Lellouch, and B. Begaud Sample size calculations for risk equivalence testing in pharmacoepidemiology J Clin Epidemiol 53 2000 1268 1274
16. S.A. Julious Sample sizes for clinical trials with normal data Stat Med 23 2004 1921 1986
17. A. Le Henanff, B. Giraudeau, G. Baron, and P. Ravaud Quality of reporting of noninferiority and equivalence randomized trials JAMA 295 2006 1147 1151
18. G. Piaggio, D.R. Elbourne, D.G. Altman, S.J. Pocock, and S.J. Evans Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement JAMA 295 2006 1152 1160